the clinical trial of the combination n1- ( 4,5-dimethyl-2-oxazolyl ) -sulfanilamide ( sulfamoxole ) and 2,4-diamino-5- ( 3,4,5-trimethoxy-benzyl ) -pyrimidine ( trimethoprim ) ( cn 3123 , nevin , supristol ) showed that , when given in the ratio of 5:1 and in a suitable dosage computed from pharmacokinetic information , it exhibited antibacterial activity and had a therapeutic effect in about 90 % of the patients .
C0041041
trimethoprim
C0279516
antibacterial